Oral Session 1: 1:20 pm – 2:10 pm

Oral #: 1 Great Auricular Nerve Morbidity after Sacrifice during Parotidectomy and the Impact on Patients, William Ryan, Palo Alto

Oral #: 2 Impact of Sentinel Node Status and Other Risk Factors on the Clinical Outcomes of Head and Neck Melanoma Patients, Stanley Leong, San Francisco

Oral #: 3 Combined therapy of anaplstic thyroid carcinoma with cetuximab and irinotecan, Seungwon Kim, Houston

Discussion

Oral #: 4 Results of Surgical Salvage After Failure of Definitive Radiation Therapy for Early-Staged Squamous Cell Carcinoma of, Ivan Ganly, New York

Oral #: 5 Voice evaluation in patients submmited to thyroid surgery without recurrent laryngeal nerve injury, Luiz Kowalski, São Paulo

Discussion

Oral Session 2: 4:15 pm – 5:35 pm

Oral #: 6 Serum protein profile analysis in patients with head and neck squamous cell carcinoma, Christine Gourin, Augusta

Oral #: 7 Deregulated expression of FANCA and GSTP1 in oral squamous cell carcinoma of young patients, Suzanne Kamel-Reid, Toronto

Oral #: 8 Gene expression profiling of oral cancer from the UK and Sri Lanka; gene specific changes related to aetiology., Victor Lopes, Birmingham

Discussion

Oral #: 9 Neoadjuvant Chemoradiation W/ Rebiopsy Directed Salvage Surgery Is Associated W/ a High Rate of Laryngeal Preservation, Harold Wanebo, Providence

Oral #: 10 Endoscopic Laser Resection of Tongue Base and Oropharyngeal Wall Carcinoma: Functional and Oncologic Outcomes, Guy Petruzzelli, Maywood

Oral #: 11 Rate of complete pathological responses (pCR) to TPF induction chemotherapy in new diagnosis SCCHN, Robert Haddad, Boston

Oral #: 12 Selective neck dissection for N+ neck in head and neck SCC: a word of caution, based on a preliminary study., Claudio Cernea, São Paulo

Discussion

Monday May 16th

Oral Session 3: 8:00 am – 9:00 am

Oral #: 13 Can cDNA microarray predict nodal metastasis in patients with cancer of the head and neck?, Ehab Hanna, Houston

Oral #: 14 LEKTI Regulates Metalloproteinases and Suppresses Perineral Invasion in HNSCC, Thomas Shellenberger, Houston

Oral #: 15 Three-dimensional analysis of p53 mutations in head and neck squamous cell carcinoma, Christopher Lansford, Ann Arbor

Discussion

Oral #: 16 CpG-motifs as adjuvants for Peptide-based Immunotherapy for HPV 16-associated Cancer, Duane Sewell, Philadelphia

Oral #: 17 The Insulin-like Growth Factor-1 Receptor in Squamous Cell Carcinoma of the Head and Neck, Mark Jameson, Charlottesville

Oral #: 18 Over-expression of CLDN1 in oral carcinoma and its correlation with EGFR activation, Suzanne Kamel-Reid, Toronto

Discussion

Oral #: 19 IRX-2 Immunotherapy of Head and Neck Cancer, John Hadden, Farmingdale

Oral #: 20 In Vivo Optical Coherence Tomography of the Human Oral Cavity and Oropharynx, James Ridgway, Irvine

Oral #: 21 The Role of PET/CT Fusion in the Staging and Management of Primary Head and Neck Cancers, Alia Hdeib, Baltimore

Discussion

Oral #: 22 Headpin: An Endogenous and Exogenous Suppressor of Angiogenesis in HNSCC, Thomas Shellenberger, Houston

Oral #: 23 Tobacco Smoke Activates the EGFR Signaling Through Activation of the Protooncogene C-SRC, Dimitrios Moraitis, New York

Discussion

Oral #: 24 Quality of life after total laryngectomy, Rehan Kazi, London

Oral #: 25 Supraglottic and Supracricoid laryngectomy for advanced larynx cancer, David Goldenberg, Baltimore

Oral #: 26 Transoral laser surgery for pharyngeal or pharyngo-laryngeal carcinomas, Jürg Kutter, Lausanne

Oral #: 27 Mature Results of Phase II Multi-institute RADPLAT for T4 HNSCC (RTOG 9615), K. Thomas Robbins, Springfield

Discussion

Oral #: 28 Neck Dissection Impairment Index: A Disease Specific Measure Used to Evaluate Impairment After Neck Dissection, Douglas Chepeha, Ann Arbor

Oral #: 29 Twelve-year Experience with the Multimodal Intensification Regimen for Advanced Resectable Squamous Cell Cancer of the O, Enver Ozer, Columbus

Oral #: 30 Standardized Care Protocol for Alcohol Withdrawal in Post-operative Head and Neck Cancer Patients, Christopher Lansford, Ann Arbor

Discussion

Oral #: 31 Levels of the Major Urinary Metabolite of PGE2 (PGE-M) are Increased in Smokers. Evidence for a Noninvasive Biomarker., Neil Gross, New York

Oral #: 32 Pituitary Tumor Transforming Gene (PTTG) Induces Genomic Instability in Thyroid Cancer., Dae Kim, Birmingham

Discussion

AHNS 2005 Annual Meeting Support

PLATINUM LEVEL SUPPORT
Merck

SILVER LEVEL SUPPORT
Pentax Medical Company
Stryker Leibinger

BRONZE LEVEL SUPPORT
Fanconi Anemia Research Fund, Inc.
Karl Storz Endoscopy

Support as of March 1, 2005